Search Results

Lu-177 DOTATATE + Triapine in GEP-NETs << Back Phase 2 Trial: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors DRUG/TREATMENT: LUTATHERA (Lu-177) + Triapine CLINICALTRIALS.GOV IDENTIFIER: NCT05724108 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=ptDSlj3Neao June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study https://www.youtube.com/watch?v=rK0NSdorBnk April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study DESCRIPTION: This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI Dr. Chauhan's presentation slides can be downloaded here: Dr. Chauhan Presentation on Lu-177 DOTATATE + Triapine Trial .pptx Download PPTX • 16.18MB 2023 NANETS Abstract shows the combination of Triapine and Lu-177 DOTATATE was safe with preliminary efficacy signals.

Join NCF for Atlanta. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page READ THE EVENT BLOGPOST ABOUT The Neuroendocrine Cancer Foundation (NCF) and Emory Winship Cancer Institute hosted a free, in-person educational conference designed specifically for people living with neuroendocrine cancer and their caregivers. This one-day program brought together leading experts from Emory University, the University of Alabama at Birmingham, and Vanderbilt University to share practical, up-to-date information on the diagnosis and management of neuroendocrine cancer. Local and regional neuroendocrine cancer specialists presented the latest insights in NET care, including multidisciplinary approaches to surgery; advances in liver-directed therapy, systemic treatments, PRRT, and clinical trials; and emerging research on GLP-1 agents and neuroendocrine tumors. In addition to expert-led presentations, attendees heard patient stories and had the opportunity to engage directly with specialists during live Q&A sessions. The interactive format helped empower patients and caregivers with knowledge, confidence, and a clearer understanding of available treatment options and care pathways. Special thanks to Dr. Udhayvir Grewal for collaborating with NCF to make this event possible. LOCATION Starvine Ballroom, Emory Conference Center Hotel 1615 Clifton Rd N E, Atlanta, GA 30329 AGENDA & SPEAKER PRESENTATIONS SPEAKER BIOS To help attendees continue learning and revisit the information shared during the program, presentation slides are available for download. Simply click on the presentation titles above to access speaker slides and related resources. Welcome & Introductions https://www.youtube.com/watch?v=Fc73UnhygB0 A Patient Journey https://www.youtube.com/watch?v=KPwJeAn7ybA Multidisciplinary Approach to Surgery for NET https://www.youtube.com/watch?v=ivcEGDTSQdM 1_Concors_Multidisciplinary Approach to Surgery for NET .pdf Download PDF • 2.28MB Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors https://www.youtube.com/watch?v=UK9Own5KJJw 2_Lilly_Liver-Directed Therapy .pdf Download PDF • 6.09MB Understanding Your Scans and PRRT: How Imaging Guides Treatment https://www.youtube.com/watch?v=eMpEhwRTQcY 3_Cole_Understanding your scans and PRRT .pdf Download PDF • 5.94MB Preparing for PRRT: What Patients Need to Know https://www.youtube.com/watch?v=0Bnhvy_-ynw 4_Muzahir_Preparing for PRRT What Patients Need to Know .pdf Download PDF • 7.74MB Systemic Therapy for Neuroendocrine Cancer: What Patients Need to Know https://www.youtube.com/watch?v=_Zqg2bT0V7k 5_Gupta_Systemic Therapy for Neuroendocrine Cancer What Do I Need to Know .pdf Download PDF • 1.04MB Q&A Session + Expert Panel #1 https://www.youtube.com/watch?v=386fjC34MJQ How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies? https://www.youtube.com/watch?v=0xmNEqt0LHc 6_Po Hien Ear_How Do GLP1 Agents Factor Into Neuroendocrine Cancer Care .pdf Download PDF • 28.84MB What It Means To Be Part of a Clinical Trial https://www.youtube.com/watch?v=cUtC08cS6fU 7_Halperin_Clinical Trials What It Means to Be Part of a Clinical Trial .pdf Download PDF • 407KB Clinical Trials: What's on the Horizon? https://www.youtube.com/watch?v=6Qt8nDQ8oEQ 8_Grewal_Clinical Trials .pdf Download PDF • 5.38MB Q&A Session + Expert Panel #2 https://www.youtube.com/watch?v=vUvqXavnfEM The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Join NCF for Sep2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=_dE7__jhf9I ABOUT The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Download Presentation Slides >>> ABOUT DR. UDHAYVIR SINGH GREWAL Udhayvir Singh Grewal, MD Assistant Professor of Medical Oncology Winship Cancer Institute Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 9: PRRT (PART II) Download a Transcript of this Episode >> Listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health >> Listen to Episode 10: PRRT (Part Three) with Josh Mailman >> ABOUT THIS EPISODE Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. MEET DR. MARTIN AUERBACH Dr. Auerbach is the Director of Nuclear Medicine at the Westwood and Santa Monica UCLA Hospitals, and Associate Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine at the UCLA Santa Monica and Westwood Hospital, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes, and monitoring of cancer treatment. TOP 10 PRRT QUESTIONS 1. Who is eligible for PRRT? When considering PRRT, is there a minimum or maximum tumor size? What is the effect if a patient receives half the planned dose or a delay in receiving a dose due to low counts? 2. How do you decide on doses of radioactive agents in PRRT? Do they consider the individual’s weight or does everyone get the same dose? 3. What are the side effects of PRRT and how are they managed? 4. Do you continue SSA with PRRT and if so when should one receive it? 5. Can people have carcinoid crisis with PRRT? If so, how is this treated? 6. When or how often are labs done? Which labs and what are you looking for? 7. When do you do imaging? Which imaging to you do? 8. When would you expect to see a response with PRRT and what is the statistics about the shrinkage or response that is expected? 9. For those who have received 4 doses of Luthatera, what happens if/when there is progression, can PRRT be repeated? Can people have more than 4 doses of Lutathera? 10. What is the difference between alpha and beta PRRT? How would you decide between the alpha or beta PRRT? ADDITIONAL RESOURCES Read the LACNETS Blog Post "These Four Letters: PRRT" >> Click here for additional PRRT Resources >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go Back to NCF Events Page "LUNCHEON WITH THE EXPERTS" With Dr. Jonathan Strosberg No registration needed. Date: July 23, 2026 Time: Noon Eastern (9 AM Pacific) Here are the viewing options on Thursday, July 23rd, at Noon Eastern (9 AM Pacific): The Webinar will be live on Facebook Live (under Events) and YouTube Live . Drop your questions for Dr. Strosberg to answer in the comments on Facebook or chat on YouTube. “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available afterward. ABOUT JONATHAN STROSBERG, MD Gastrointestinal Oncology Moffitt Cancer Center, Tampa, Florida Jonathan Strosberg, MD, is a professor in the Department of Gastrointestinal Oncology at the Moffitt Cancer Center in Tampa, FL, specializing in the management of neuroendocrine malignancies. He is also section head of the Neuroendocrine Tumor Division at the Moffitt Cancer Center. He is a graduate of Harvard University and Weill Cornell Medicine. He completed his fellowship in medical oncology and hematology at the Moffitt Cancer Center. Dr. Strosberg has published more than 20 articles and book chapters on the diagnosis and management of neuroendocrine malignancies, including first-author publications in The New England Journal of Medicine , the Journal of Clinical Oncology and The Lancet Oncology . He has also authored 13 articles for UpToDate . He has served as president of the North American Neuroendocrine Tumor Society, and he serves on the National Comprehensive Cancer Network Neuroendocrine Guidelines Committee. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

<< Go back to the Podcast page EPISODE 42: NEUROENDOCRINE CANCER STRAIGHT TALK Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, medical oncologist and NET expert, Dr. Diane Reidy-Lagunes engages in an open and honest discussion on sensitive topics including sexual health, family planning and end-of-life discussions. She also answers common questions regarding cannabis use with cancer as well as the relationship between sugar and cancer. Dr. Reidy shares information and insights from her decades of experience as well as from the award-winning “Cancer Straight Talk” podcast from Memorial Sloan Kettering Cancer Center (MSKCC) she created and hosted, and she relates these topics to NET patients and their loved ones. MEET DR. DIANE REIDY-LAGUNES Dr. Diane Reidy-Lagunes will join the Department of Medicine (DOM) as chief of the Division of Medical Oncology, effective April 1, 2025. In addition to her role with DOM, Dr. Reidy-Lagunes will also hold an appointment as Associate Vice President for Oncology Services for Duke University Health System. Dr. Reidy-Lagunes comes to Duke from Memorial Sloan Kettering Cancer Center (MSKCC), where she served as the vice chair of Medicine focused on coordination of care in MSKCC Regional Care Network. Her previous roles included president of MSKCC’s Medical Staff, associate deputy physician-in-chief for clinical operations in the Regional Care Network, physician liaison for the Patient and Family Advisory Council on Quality, clinical director for the GI oncology service, and co-director of the Medical Oncology/Hematology Fellowship Program in the Department of Medicine. During the COVID-19 crisis in New York City, she served as chief of clinical care as part of the Hospital Incident Command System at MSKCC. Additionally, she is the creator and host of an award-winning monthly podcast called "Cancer Straight Talk" from MSKCC which connects patients to cancer experts with the goal of having evidenced-based conversations on a variety of topics in cancer care. As a researcher, Dr. Reidy-Lagunes focuses on developing methods to integrate molecular-based therapies into the treatment of neuroendocrine and adrenal tumors. She is a member of the National Cancer Institute Task Force on Neuroendocrine Tumors and the National Cancer Care Network Guidelines, and she is a former board member of the North American Neuroendocrine Tumor Society. She has received numerous awards and honors, including the Paul Sherlock Resident Housestaff Teaching Award and recognition as one of Castle Connolly's Top Doctors. TOP TEN QUESTIONS: What is cancer? Is NET cancer? Should I follow a certain diet? Does sugar feed cancer? Can I exercise if I have metastatic neuroendocrine cancer? What does having neuroendocrine cancer mean for my romantic life? How does it affect dating? What does having neuroendocrine cancer mean for my sexual health? What does having neuroendocrine cancer mean for fertility and family planning? Can I have children? How do I talk to my kids about cancer? How will I know when it’s time for end-of-life discussions? Should I consider cannabis? What advice do you have about improving communication with my doctor? RESOURCES LISTEN MSK’s Cancer Straight Talk Podcast Series with Dr. Diane Reidy Episodes mentioned in this podcast: Episode 2 - Understanding the Basics of the “C-word”: What is Cancer with Dr. Matthew Matasar Episode 6 - Sugar and Cancer: Friend or Foe with Dr. Santosha Vardhana Episode 5 -Making Every Step Count: The Role of Exercise and Cancer Episode 34 - How Exercise Can Help Treat and Prevent Cancer with Dr. Lee Jones Episode 35 - Dating After a Cancer Diagnosis Episode 20 - A Man’s Guide to Sex and Cancer Episode 59 - Preserving Fertility During Cancer Treatment: Options, Costs and Success Rates Episode 56 - How to Talk to Children About Cancer Episode 23 - What’s the Hash on the Little Green Plan (Cannabis) and Cancer? MSK’s Death over Dinner The LACNETS Podcast Episode 37: Supportive Oncology for Neuroendocrine Cancer WATCH https://www.youtube.com/watch?v=ef4GurXr0C8 https://www.youtube.com/watch?v=FiYogD5g_9A DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors << Back CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT03375320 DRUG/TREATMENT: Cabozantinib PHASE: 3 STATUS: Closed SPONSOR: National Cancer Institute (NCI) Update - November 9, 2025 https://www.youtube.com/watch?v=balUaCFLceI Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Download the transcript here >>> Update - October 18, 2025 Exelixis Announces Positive Results for CABOMETYX® in Lung and Thymic Neuroendocrine Tumors At ESMO 2025, researchers reported that CABOMETYX® (cabozantinib) significantly delayed tumor growth in people with advanced lung or thymic neuroendocrine tumors—reducing the risk of disease progression or death by 81% compared to placebo. These results come from a subgroup of the phase 3 CABINET trial, which led to FDA and European approvals earlier this year for advanced pancreatic and extra-pancreatic NETs. Why this matters to patients: Lung and thymic NETs are rare and often have few treatment options. CABOMETYX offers a new targeted therapy that may help keep these tumors from growing. Read the full press release here >>> Update - March 26, 2025 A New Treatment Option has been FDA approved for those living with NET. For details, see the press release . UPDATE - September 16, 2024 On Sept 16, 2024, LACNETS interviewed incoming NANETS president, Dr. Jennifer Chan from Dana Farber Cancer Institute following her presentation on the updated, results of the CABINET trial at the medical and scientific meeting, ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. The presentation was titled Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses. https://www.youtube.com/watch?v=4iWtw3qmrBs Watch our latest interview on Sept 16, 2024 with Dr. Jennifer Chan at ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. For more information, read our blogpost: Positive Results of the Cabinet Trial Show Cabozantinib As a New Effective Treatment in Advanced Neuroendocrine Tumors . Read more in the latest NEJM article released Sept 16, 2024: Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. UPDATE - October 25, 2023 Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future. Click here to read the detailed results of the CABINET trial here: Business Wire - "Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 " OncLive - "Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors" https://www.youtube.com/watch?v=VonfcmeellU Watch this exclusive video interview with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain. UPDATE - Aug 24, 2023 The Alliance for Clinical Trials in Oncology announced that the CABINET trial (NCT03375320) showed positive findings with cabozantinib having efficacy. The CABINET trial is a phase 3 randomized, double-blinded study evaluating cabozantinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors (PNET) or advanced extra-pancreatic neuroendocrine tumors (carcinoid tumors) who experienced progression after prior systemic therapy. The trial is now being stopped early. It will be unblinded, meaning the patients will find out if they have been receiving placebo and those who have will have the possibility of receiving cabozantinib. The findings will be discussed with the U.S. Food and Drug Administration. Detailed results from the trial will be presented at an upcoming scientific meeting. To read the announcement, go to https://bit.ly/A021602-Interim or https://www.onclive.com/view/cabozantinib-efficacy-prompts-cabinet-trial-unblinding-in-advanced-pancreatic-and-extra-pancreatic-nets. https://www.youtube.com/watch?v=2H_SChk3gxw Dr. Jennifer Chan Discusses CABINET: Cabozantinib DESCRIPTION: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors that, when blocked, may slow tumor growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Jennifer A Chan, MD, MPH Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI)

Join NCF for Jan2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Q3ji1Zdo9oE ABOUT Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. ABOUT DR. METZ David Metz, MD Gastroenterologist University of Pennsylvania School of Medicine Retired Professor CE of Medicine, Perelman School of Medicine, Co-director, GI Physiology Laboratory, Director, Acid Peptic Disorders Specialty Program, Co-director, Penn Program for Swallowing Disorders, Associate Chief for Clinical Affairs, Division of Gastroenterology, Co-director, University of Pennsylvania Neuroendocrine Tumor Program After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. RESOURCES Listen Read Our Cancer Stories: "Understanding Gastric Neuroendocrine Tumors" "Stages of Gastric Neuroendocrine Tumors" "Hormone Therapy for Gastric Neuroendocrine Tumors" "Types and Grades of Gastric Neuroendocrine Tumors" The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Join NCF for Jan2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Vb7aH06UWrE Download PowerPoint Slides >>> Some Topics Covered: Types of Functional Neuroendocrine Tumors, Hormone-producing, Carcinoid Syndrome, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Diarrhea, Flushing, Hypoglycemia, Carcinoid Heart Disease, Cushing Syndrome, Somatostatinoma. ABOUT Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. THANKS TO OUR SPONSORS PRESENTING SPONSOR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC << Back A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab IDENTIFIER ( ClinicalTrials.gov ) : NCT05142696 DRUG/TREATMENT : LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab PHASE : 1b / 2 STATUS : Recruiting SPONSOR : Novartis Pharmaceuticals DESCRIPTION: https://www.youtube.com/watch?v=0h8ye62LDT0 Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC ." Recorded: June 20, 2024 This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Novartis Pharmaceuticals EMAIL: novartis.email@novartis.com PHONE: 1-888-669-6682 RELATED RESOURCES : Clinical Trials Using Lutetium Lu 177 Dotatate - NCI https://www.youtube.com/watch?v=oCHpfmQLeJM "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD

<< Go back to the Podcast page EPISODE 52 - Spotlight on Genetic Counselors Download a Transcript of this Episode >>> ABOUT THIS EPISODE Who is a genetic counselor, and who should see one? How do they fit into the neuroendocrine cancer care team? In this episode, Samantha Greenberg, PhD, MS, MPH, CGC, Director of the UT Southwestern Genetic Counseling Program, demystifies genetic counseling and testing for NET patients and their families. She explains what to expect before, during, and after a consultation—and how results can impact care, family members, and future planning. TOP TEN QUESTIONS Role & Training 1. What is a genetic counselor? What training is required? What’s your role in the care team? Genetic Counseling & NETs 2. How are genetic counselors involved in NET care? 3. Who should get genetic testing? Do all NET patients need it? What if more than one family member has NET? Do you also see family members without a diagnosis? 4. How does one’s age play a role? Testing Basics 5. Genetic vs. genomic vs. NGS—what are these terms? How do patients know they’re getting the right test? 6. Walk us through a genetic counseling consultation—before, during, after. Results & Implications 7. What if the results are positive? How do you guide patients and families? What if the results are negative or inconclusive? How accurate are tests? 8. What is a “variant of unknown significance”?9. Can environment or toxins cause hereditary mutations? Practical Guidance 10. How can patients find the right genetic counselor? Do they need to be someone who specializes in neuroendocrine cancer? MEET SAMANTHA GREENBERG Samantha Greenberg, PhD, MS, MPH, CGC Pronouns: she/her Director, UT Southwestern Genetic Counseling Program Assistant Professor School of Health Professions Samantha Greenberg is the founding program director of the UT Southwestern Genetic Counseling Training Program. She received her Master of Science degree in genetic counseling and public health from the University of Michigan after teaching middle school science with Teach For America in Tulsa, Oklahoma. She recently completed her Ph.D. at the University of Utah. As a cancer genetic counselor, Greenberg has provided clinical care across a variety of indications and facilitated the development of multidisciplinary teams and genetics clinics for patients with prostate cancer, von Hippel-Lindau syndrome, and paraganglioma/pheochromocytoma. She is the co-director of the paraganglioma program at UT Southwestern, which recently received a Center of Excellence designation from Pheo Para Alliance. Her passion for raising awareness on the genetics of neuroendocrine tumors stems from working with patients and a curiosity for how to optimize identification of patients with hereditary risk. RESOURCES Watch https://www.youtube.com/watch?v=VWMdD5LJAFo Genetics of NET: Do I Need Genetic Testing with Samantha Greenberg (Feb 2023) https://www.youtube.com/watch?v=wgEoFAQ7lp8 Deciphering Genetics & Genomics in Neuroendocrine Cancers with Dr. Kimberly Perez (Feb 2025) EXPLORE FindaGeneticCounselor.com https://pheopara.org/ DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC << Back A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy IDENTIFIER ( ClinicalTrials.gov ) : NCT06736418 DRUG/TREATMENT : 225Ac-ABD147 PHASE : 1A/B STATUS : Recruiting SPONSOR : A bdera Therapeutics Inc. https://www.youtube.com/watch?v=PDR0flgpAXE DLL-3-RLT Presentation Slides .pdf Download PDF • 863KB DESCRIPTION: This is an open-label, Phase 1a/1b, first-in-human study testing a new targeted treatment called 225Ac-ABD147 for people with locally advanced or metastatic small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung. All participants must have previously received platinum-based chemotherapy. What is 225Ac-ABD147? 225Ac-ABD147 is a DLL3-targeting antibody fragment, a small, engineered piece of an antibody that targets cancer cells with a marker called delta-like ligand 3 (DLL3) . It is attached to a special linker-chelator that holds a radioactive particle ( Actinium-225 ) so that a precise dose of radiation can be delivered directly to DLL3-positive cancer cells. The study has two parts: Phase 1a and Phase 1b . Phase 1a: Safety, Dosing & Early Signals Phase 1a is designed to understand: Safety and side effects How the drug moves through the body (PK and biodistribution) Early signs of effectiveness The safest and most appropriate dose levels A small group of participants will also receive an experimental imaging agent, 111In-ABD147 , to help researchers see how the treatment travels and where it binds in the body. Phase 1b: Expanded Testing at Selected Doses Phase 1b uses the dose levels identified in Phase 1a to further evaluate: Safety How well the treatment works for SCLC and LCNEC This phase helps researchers better understand the potential benefit of 225Ac-ABD147 in these cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Abdera Therapeutics Inc. EMAIL: AbderaClinicalTrials@abderatx.com PHONE: 1 650-434-4093 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.